SCHEMBL25899459

SCHEMBL25899459

NCC1O[C@H](OP(=O)(O)OP(=O)(O)OC[C@H]2O[C@@H](n3cnc4c(=O)[nH]c(N)nc43)C(O)C2O)C(O)C(O)[C@@H]1O

nearest known ligand 0.73

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
FUT5 Q11128 1/20 0.73
TGM2 P21980 1/20 0.71
KRAS P01116 6/20 0.67
NT5E P21589 1/20 0.67
P2RX3 P56373 2/20 0.62
P2RY2 P41231 3/20 0.61
P2RY4 P51582 1/20 0.61
P2RY6 Q15077 1/20 0.61
DCPS Q96C86 1/20 0.58
P2RY1 P47900 3/20 0.58
SRC P12931 1/20 0.58
P2RX1 P51575 1/20 0.58
P2RX4 Q99571 1/20 0.58
P2RX2 Q9UBL9 1/20 0.58
ALDH1A1 P00352 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
HINT1 P49773 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25962935 1.00 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL25891152 1.00 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29456613 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29375573 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL30646153 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29581866 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29391942 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29351374 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL29527687 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3
SCHEMBL30973673 0.94 FUT5 (0.73) FUT5TGM2KRASNT5EP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230235082-A1 SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME GLYCO-THERAPY BIOTECHNOLOGY CO., LTD. (CN) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230235082-A1 SITE-SPECIFIC ANTIBODY CONJUGATES AND THE METHODS FOR PREPARATION OF THE SAME FUT5, FUT6, SIGLEC7 FUT5 1/4885TGM2 179/4885KRAS 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.